The off-label use of approved pharmaceuticals outside the authorized status is implemented in pharmacotherapy of many diseases, especially for rare diseases and in cases of therapy resistance. The German regulations are presented and analyzed and the relative literature is discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00393-011-0901-8 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!